| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Minzasolmin targets α-synuclein, a protein that misfolds and oligomerizes in Parkinson's disease and other synucleinopathies. The compound is an inhibitor (blocker/antagonist) of α-synuclein oligomerization. As the purified R-enantiomer of NPT200-11, it is designed to prevent the misfolding and aggregation of α-synuclein. By inhibiting α-synuclein oligomerization, Minzasolmin aims to modify the disease course in Parkinson's disease. The compound is orally bioavailable and brain-penetrant, enabling central nervous system targeting.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Minzasolmin is an inhibitor of α-synuclein oligomerization. As the purified R-enantiomer of NPT200-11, it targets α-synuclein misfolding and aggregation. The compound has been characterized for its ability to inhibit α-synuclein oligomerization in cell-free and cell-based assays. It is a valuable research tool for studying α-synuclein aggregation mechanisms and for developing therapeutic strategies for Parkinson's disease. Detailed in vitro characterization data are available in the primary literature. The compound's brain-penetrant properties facilitate in vitro studies in neuronal cell models.
|
| ln Vivo |
In vivo studies of Minzasolmin have been reported in the context of Parkinson's disease research. As an orally bioavailable and brain-penetrant α-synuclein misfolding inhibitor, the compound has been evaluated in preclinical animal models of Parkinson's disease. Minzasolmin is being developed as a disease-modifying therapy for Parkinson's disease. Specific in vivo efficacy data and animal model studies are available in the primary literature. The compound's oral bioavailability and brain penetration support its potential for clinical development. Further clinical studies are ongoing.
|
| Enzyme Assay |
For α-synuclein oligomerization inhibition assays, recombinant α-synuclein protein is incubated with varying concentrations of Minzasolmin under aggregation-promoting conditions. Oligomerization is monitored using specific antibodies that recognize α-synuclein oligomers (e.g., A11 antibody) or by size-exclusion chromatography. The compound's ability to inhibit oligomer formation is assessed. IC50 values are calculated from dose-response curves. For cell-based assays, neuronal cells expressing α-synuclein are treated with compound and oligomer levels are measured by immunofluorescence or Western blot. Assays are performed in replicate with vehicle controls.
|
| Cell Assay |
For in vitro cellular assays, neuronal cell lines (e.g., SH-SY5Y cells) or primary neurons expressing α-synuclein are cultured in appropriate media under standard conditions (37°C, 5% CO2). Minzasolmin is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. α-Synuclein oligomerization is assessed using oligomer-specific antibodies, immunofluorescence, or biochemical fractionation. Cell viability and cytotoxicity are assessed using MTT or LDH assays. Neuronal degeneration markers may be measured. Each concentration is tested in replicate wells with vehicle controls.
|
| Animal Protocol |
For in vivo animal studies, Minzasolmin is typically administered orally (by gavage) due to its oral bioavailability. Dosing regimens vary by study objective. In Parkinson's disease models, animals (typically mice or rats) may be administered α-synuclein pre-formed fibrils (PFFs), use transgenic α-synuclein overexpression models, or use toxin-induced models (e.g., MPTP). Minzasolmin is formulated in suitable vehicles for oral administration. Dopaminergic neuron degeneration is assessed by immunohistochemistry for tyrosine hydroxylase (TH). Motor function is assessed using behavioral tests. α-Synuclein pathology is assessed by histopathology. All procedures follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Minzasolmin indicate it is orally bioavailable and brain-penetrant. The compound has a molecular weight of 425.59, formula C23H31N5OS, and CAS number 1802518-92-8. Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. The compound is the purified R-enantiomer of NPT200-11. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are reported in the primary literature. The compound's brain penetration supports its central nervous system targeting.
|
| Toxicity/Toxicokinetics |
According to available safety information, Minzasolmin is intended for research use only and not for human therapeutic applications outside of clinical development. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available outside of clinical trial settings.
|
| References | |
| Additional Infomation |
Minzasolmin is being investigated in the clinical trial NCT05543252 (an extended study evaluating the long-term efficacy, safety, and tolerability of Minzasolmin (UCB0599) in patients with Parkinson's disease). See also: Carbidopa (related drugs).
Minzasolmin (UCB0599; (R)-NPT200-11) is an inhibitor of α-synuclein misfolding and oligomerization, developed as an orally bioavailable and brain-penetrant small molecule for disease-modifying therapy in Parkinson's disease. It has a molecular weight of 425.59 and formula C23H31N5OS. The compound is the purified R-enantiomer of NPT200-11. It is for research use only with no regulatory approvals reported to date. |
| Molecular Formula |
C23H31N5OS
|
|---|---|
| Molecular Weight |
425.59
|
| Exact Mass |
425.224
|
| CAS # |
1802518-92-8
|
| Related CAS # |
(S)-Minzasolmin;1802518-91-7;(Rac)-Minzasolmin;1802518-63-3
|
| PubChem CID |
118279413
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
556
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S1C(C(N[C@@H](CC2C3=C(NC=2)C=CC=C3)CCCC)=O)=CN=C1N1CCN(C)CC1
|
| InChi Key |
GDFWCSZNQVAQGR-GOSISDBHSA-N
|
| InChi Code |
InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m1/s1
|
| Chemical Name |
N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3497 mL | 11.7484 mL | 23.4968 mL | |
| 5 mM | 0.4699 mL | 2.3497 mL | 4.6994 mL | |
| 10 mM | 0.2350 mL | 1.1748 mL | 2.3497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05543252
Conditions:Parkinson's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT05845645
Conditions:Healthy Study ParticipantsLink: https://clinicaltrials.gov/ct2/show/NCT04658186
Conditions:Early-stage Parkinson's Disease
Title:A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
Status:Completed
updateDate:2021-05-06
Ctid:NCT04875962
Link: https://clinicaltrials.gov/ct2/show/NCT04875962
Conditions:Parkinson's DiseaseProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
